美国食品药品监督管理局（FDA）已批准礼来公司旗下药物Zepbound（活性成分：Tirzepatide）的标签扩展申请。此次更新正式将四剂量规格的单患者使用Kwikpen纳入其获批适用范围。这一举措旨在提升用药便利性，满足个体化治疗需求。
美国食品药品监督管理局（FDA）已批准礼来公司旗下药物Zepbound（活性成分：Tirzepatide）的标签扩展申请。此次更新正式将四剂量规格的单患者使用Kwikpen纳入其获批适用范围。这一举措旨在提升用药便利性，满足个体化治疗需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.